Opendata, web and dolomites

CMI2T IA SIGNED

Harmless Clostridium bacteria as a highly targeted, continuous delivery system for immunomodulatory anti-cancer drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CMI2T IA" data sheet

The following table provides information about the project.

Coordinator
DualTpharma 

Organization address
address: OXFORDLAAN 55
city: MAASTRICHT
postcode: 6229 EV
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.dualtpharma.com
 Total cost 115˙625 €
 EC max contribution 115˙625 € (100%)
 Programme 1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-02-2016
 Funding Scheme CSA
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DualTpharma NL (MAASTRICHT) coordinator 115˙625.00

Map

 Project objective

DualTPharma (DTP) is a new venture developing a highly-potent and proprietary line of targeted pharmaceuticals for personalised cancer treatment. Our mission is to broaden our current pipeline by developing a new class of dual drugs for cancer treatment which are well tolerated and can be taken orally.

This novel solution comprises the application of non-pathogenic Clostridium bacteria as a novel tumour delivery vehicle for anti-cancer drugs to increase immunotherapy efficacy. Even though DTP has a multi-disciplinary team available in the oncology field, we lack the required expertise and skills in the bacterial genetic field to test the feasibility and lead the development of this new line of R&D. Therefore, the goal of this project, CMI2T IA, is to hire an Innovation Associate with expertise in the bacterial genetic field for our company, to determine the feasibility of this novel solution. The successful candidate is preferably a microbiologist with an interest in bacterial applications in cancer treatment and with strong expertise in bacterial genetics. During the first 12 months, the innovation associate will be involved with both technical and business-related activities. (S)he will be responsible for establishing the new line of R&D, with activities ranging from establishing and managing a new lab to, planning research, to performing hands-on laboratory work. More specifically, the research activities will include genetic modification of bacteria, and performing in vitro efficacy assays on human cell lines. From a business perspective, the Innovation Associate will critically contribute to a market study and the development of a business strategy of the new business unit.

This position will open up new career opportunities for the Innovation Associate, by obtaining transferable skills in both the business and technical field, and will leverage DTP’s growth by expanding DTP’s drug pipeline with a very novel and promising cancer drug delivery candidate.

 Deliverables

List of deliverables.
training program oncology Documents, reports 2019-04-18 13:53:34
training program business aspects Documents, reports 2019-04-18 13:53:32

Take a look to the deliverables list in detail:  detailed list of CMI2T IA deliverables.

 Publications

year authors and title journal last update
List of publications.
2014 John T. Heap, Jan Theys, Muhammad Ehsaan, Aleksandra M Kubiak, Ludwig Dubois, Kim Paesmans, Lieve Van Mellaert, Richard Knox, Sarah A. Kuehne, Phillipe Lambin, Nigel P. Minton
Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.1761
Oncotarget 5/7 2019-04-14
2016 Alexandra Mowday, Christopher Guise, David Ackerley, Nigel Minton, Philippe Lambin, Ludwig Dubois, Jan Theys, Jeff Smaill, Adam Patterson
Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress
published pages: 63, ISSN: 2072-6694, DOI: 10.3390/cancers8070063
Cancers 8/7 2019-04-14
2015 Aleksandra M. Kubiak, Nigel P. Minton
The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy
published pages: 244-254, ISSN: 0923-2508, DOI: 10.1016/j.resmic.2014.12.006
Research in Microbiology 166/4 2019-04-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CMI2T IA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CMI2T IA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

MontEENegro (2020)

Enhancing innovation management capacities of SMEs in Montenegro

Read More  

DCS-iSMEs (2019)

Design Customized Support for Innovative SMEs

Read More  

RECycle Plastics (2019)

Real-time Evaluation and Classification of Plastics

Read More